Abstract
Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.
Keywords: Amantadine, influenza virus, ion channel, neuraminidase, neuraminidase inhibitor, pandemic, pathogenesis, rimantadine
Infectious Disorders - Drug Targets
Title: Influenza Viruses: Basic Biology and Potential Drug Targets
Volume: 7 Issue: 4
Author(s): Christopher F. Basler
Affiliation:
Keywords: Amantadine, influenza virus, ion channel, neuraminidase, neuraminidase inhibitor, pandemic, pathogenesis, rimantadine
Abstract: Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.
Export Options
About this article
Cite this article as:
Basler F. Christopher, Influenza Viruses: Basic Biology and Potential Drug Targets, Infectious Disorders - Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/187152607783018745
DOI https://dx.doi.org/10.2174/187152607783018745 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.
Current Pharmaceutical Design Update on the Evidence of Statin Treatment to Reduce Plaque Vulnerability
Drug Metabolism Letters Spatio-temporal Distribution of Meningitis in HIV Patients in Northern Egypt (2000-2018)
Current HIV Research Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy A Merger of Rational Drug Design and Combinatorial Chemistry Development and Application of Peptide Secondary Structure Mimetics
Combinatorial Chemistry & High Throughput Screening Current Developments Using Emerging Transdermal Technologies In Physical Enhancement Methods.
Current Drug Delivery Immune-Inflammation in Atherosclerosis: A New Twist in an Old Tale
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Uses of the Plants Belonging to the Genus <i>Commiphora</i>
Cardiovascular & Hematological Agents in Medicinal Chemistry The Outbreak of Coronavirus Disease 2019 (COVID-19) and its Manifestation
Coronaviruses The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Current Drug Delivery C-type Lectin Receptor: Old Friend and New Player
Medicinal Chemistry Does Pharmacological Therapy Still Play a Role in Preventing Sudden Death in Surgically Treated Tetralogy of Fallot?
Mini-Reviews in Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Lipid-Protamine-DNA-Mediated Antigen Delivery
Current Drug Delivery Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry DNA and RNA Code-reading Molecules as Potential Gene Silencers in Neurobiology- What are They and what are They Good for?
Current Medicinal Chemistry - Central Nervous System Agents Ajulemic Acid (CT3) A Potent Analog of the Acid Metabolites of THC
Current Pharmaceutical Design To Seek Shelter from the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy
Current Drug Targets